search

Active clinical trials for "Influenza, Human"

Results 1571-1580 of 1970

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given...

Influenza

To provide Centers for Biologic Evaluation and Research (CBER) with sera collected from healthy children receiving the 2007-2008 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study.

Completed18 enrollment criteria

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006...

Influenza

To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).

Completed21 enrollment criteria

Vitamin D and the Influenza Epidemic

Influenza

Subjects included in ongoing vitamin d intervention trials were asked by questionnaire if they were ill with influenza during the winter season 2009/2010 to see if vitamin d supplementation prevented flu like disease.

Completed2 enrollment criteria

Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections...

Respiratory Tract InfectionsInfluenza

Purpose: The study null hypothesis is that vitamin D supplementation will not influence time to acute respiratory tract infection in sheltered accommodation residents.

Completed18 enrollment criteria

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007)...

Influenza

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over

Completed8 enrollment criteria

Electronic Health Records for Health Promotion

Influenza

The purpose of this study is to determine whether personally controlled electronic health records can be used for health promotion in a workplace setting.

Completed7 enrollment criteria

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

COVID-19Influenza A1 more

This study is designed as a prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal swabs. This study is part of the performance evaluation to support the CE conformity assessment procedures.

Completed8 enrollment criteria

Age and Response to Flu Vaccines

InfluenzaInfluenza Immunisation

The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary objective of this study is to evaluate the relationship between first influenza A virus exposure (inferred by age), vaccine history, and baseline serum antibody response to seasonal influenza vaccine in healthy adults and children.

Completed23 enrollment criteria

Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients...

Aspergillosis; PulmonaryInvasive (Etiology)

The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza. The investigators will perform an interventional non-blinded randomized controlled multicentric proof-of-concept study in patients with severe influenza admitted to the ICU. Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of care) group. Oseltamivir will be started at the discretion of the investigator. Patients in the posaconazole group will receive posaconazole prophylaxis for 7 days. addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU

Completed15 enrollment criteria

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems...

Avian InfluenzaH1N1 Influenza1 more

This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and compare the immunogenicity between an intramuscular monovalent inactivated influenza A/H7N9 virus vaccine given with and without AS03 adjuvant, and an intramuscular unadjuvanted monovalent inactivated influenza A/H3N2v virus vaccine. The primary objectives are (1) assessing the serum anti-HA hemagglutination-inhibition (HAI) response to influenza A/H7N9 antigen (with and without adjuvant) at Day 57 (approximately one month after the second study vaccination with A/H7N9 vaccine with or without AS03) and influenza A/H3N2v antigen at Day 29 (approximately one month after the study vaccination with A/H3N2v), and (2) identifying differentially expressed genes in human immune cells on Days 2, 4, and 29 (following the first study vaccination with A/H7N9 vaccine with or without AS03) and on Days 30, 32, and 36 (following the second study vaccination with A/H7N9 vaccine with or without AS03), compared to baseline assessments performed prior to each study vaccination (Days -7, 1, and 29).

Completed51 enrollment criteria
1...157158159...197

Need Help? Contact our team!


We'll reach out to this number within 24 hrs